TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18782787
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standardized perioperative therapy without fenoldopam)
Study: 11952069
Drug: Continuous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous midazolam infusion (n = 21)
Study: 11952069
Drug: Diazepam infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam infusion (n = 19)
Study: 7723546
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus antibody 33B3.1 (n = 51)
Study: 1952306
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg methotrimeprazine (Levoprome, Nozinan)
Study: 1952306
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg meperidine (Demerol) combined with 50 mg dimenhydrinate (Dramamine, Gravol)
Study: 9278199
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times daily)
Study: 22849762
Drug: Moogoo Udder
Normalized name: Corona Udder Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moogoo Udder Cream®
Study: 17545739
Drug: memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (20 mg/d)
Study: 15887425
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/d) added to ongoing statin therapy
Study: 15887425
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ongoing statin therapy
Study: 7908877
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium cromoglycate solution and oral oxatomide
Study: 7908877
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo solution and oral oxatomide
Study: 1831397
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (MPA)
Study: 2970555
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) and High-dose medroxyprogesterone acetate (MPA)
Study: 28154369
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment consistent with the guidelines for AP
Study: 19233339
Drug: Attention-based rehearsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-based rehearsal (not specified in dosage or duration)
Study: 19233339
Drug: Facilitation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitation of processing at the memorized location (not specified in dosage or duration)
Study: 17118191
Drug: Micronutrient mix
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient mix (288 mg vitamin E, 375 mg vitamin C, 12 mg beta-carotene, 15 mg zinc/day)
Study: 17118191
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum concentrate (1.2 g/d)
Study: 17118191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of colostrum and micronutrient mix
Study: 8612408
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion continued
Study: 8612408
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion discontinued
Study: 8612408
Drug: TRH administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH administration (200 micrograms, two consecutive doses)
Study: 8612408
Drug: TRH administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH administration (200 micrograms, two consecutive doses) after dopamine withdrawal
Study: 2859861
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg for 4 weeks)
Study: 2859861
Drug: Metoprolol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (low dosage)
Study: 2859861
Drug: Other beta-adrenoceptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other beta-adrenoceptor blockers (acebutolol, penbutolol, pindolol)
Study: 30797394
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) implants
Study: 26691247
Drug: DEC 300
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 300 mg + Albendazole 400 mg sequential administration
Study: 26691247
Drug: DEC 300
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 300 mg + Albendazole 400 mg co-administration
Study: 26691247
Drug: DEC 300
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 300 mg + Doxycycline 100 mg co-administration
Study: 26691247
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen DEC 300 mg
Study: 22212494
Drug: 2% diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% diltiazem ointment
Study: 15595331
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) - phenobarbital, phenytoin, valproic acid
Study: 12431962
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) followed by involved-field radiotherapy (arm B)
Study: 2007102
Drug: Lidocaine (0.7,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (0.7, 1.85, and 3.7 mg/kg) infused over 15, 45, and 75 minutes
Study: 6180687
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of up to 300 mg of urushiol over three to six months
Study: 2996444
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate solution
Study: 2996444
Drug: WHO oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO oral rehydration solution
Study: 28229572
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (200 mg per day for 4 weeks)
Study: 28229572
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg per day for 4 weeks)
Study: 23871132
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate (1 g Ca as pentacalcium hydroxy-triphosphate)
Study: 16167790
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 microg x kg(‐1) and famotidine 20 mg
Study: 16167790
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received oral famotidine alone
Study: 12797394
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin prophylaxis (200 mg/2x12h)
Study: 12797394
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard perioperative antibiotic prophylaxis with 2 g cefotiam)
Study: 10782653
Drug: both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both agents
Study: 21716127
Drug: Beclomethasone nasal
Normalized name: beclomethasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone nasal spray
Study: 26812804
Drug: Active hypnotic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active hypnotic drug
Study: 22352703
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion
Study: 17095129
Drug: Menjugate vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menjugate vaccine stored at room temperature (25+/‐2 degrees C)
Study: 17095129
Drug: Menjugate vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menjugate vaccine stored at 2‐8 degrees C
Study: 9690722
Drug: Rennie (calcium‐magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rennie (calcium‐magnesium carbonate) 1360 mg
Study: 27977057
Drug: Otlertuzumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otlertuzumab (20 mg/kg) weekly by IV infusion for two 28-day cycles then every 14 days for four 28-day cycles + IV bendamustine (70 mg/m2) on Days 1 and 2 of each cycle for up to six 28-day cycles
Study: 26041316
Drug: Large dose
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dose remifentanil (0.30 μg/kg/min) + low-dose naloxone (0.25 μg/kg/h)
Study: 26041316
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose remifentanil (0.1 μg/kg/min)
Study: 26041316
Drug: Large dose
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dose remifentanil (0.30 μg/kg/min)
Study: 23841967
Drug: Gesture Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gesture Therapy (virtual reality rehabilitation)
Study: 11136169
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (creatinine < 2.3 mg/dL)
Study: 9264833
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Transfer factor for three months
Study: 3612828
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment format (communication skills followed by sexual skills)
Study: 29489709
Drug: Cleansing solution
Normalized name: Cleansing Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing solution and dressing material used before insertion and after removal of SPC.
Study: 20851307
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (1.7 g daily for 3 months)
Study: 21966763
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/day for six months)
Study: 2766869
Drug: Short-course ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course ceftriaxone therapy (4, 6, and 7 days depending on the pathogen)
Study: 2766869
Drug: Standard-length ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-length ceftriaxone therapy (twice as long as short-course)
Study: 800972
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of muzolimine (80 mg) and spironolactone (300 mg)
Study: 800972
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of furosemide (80 mg) and spironolactone (300 mg)
Study: 800972
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and spironolactone (300 mg)
Study: 23539903
Drug: Ommaya reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ommaya reservoir treatment
Study: 23539903
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment methods
Study: 19800704
Drug: Novel SIB
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel SIB strategy with prescribed mean doses of 46.8 Gy to PTV(risk), 50.6 Gy to PTV(pre_chemo), and 58.1 Gy to PTV(post_chemo) in 25 fractions.
Study: 17074942
Drug: First acute
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First acute treatment step
Study: 17074942
Drug: Second acute
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second acute treatment step
Study: 17074942
Drug: Third acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third acute treatment step
Study: 17074942
Drug: Fourth acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth acute treatment step
Study: 11771024
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg/day for the first week and 100 mg/day for the following 5 weeks
Study: 11771024
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose starch tablets, 1 tablet/day for 6 weeks)
Study: 7508219
Drug: LPS/NAME group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS/NAME group (NSR, LPS, and continuous infusion of 50 micrograms/kg per minute of N‐nitro‐L‐arginine methyl ester)
Study: 27017701
Drug: Cytoflavin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (10 mL in 200 mL of 0.9% sodium chloride for 10 days, then 2 tablets twice a day for 25 days)
Study: 27017701
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with oral antidiabetic drugs (metformin monotherapy or combined therapy)
Study: 23170993
Drug: Therapy dog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy dog visits (average duration 12 minutes)
Study: 7878632
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g daily)
Study: 27568006
Drug: Infant massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant massage therapy administered by the mother until term equivalent age (TEA)
Study: 27568006
Drug: Infant massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant massage therapy
Study: 23942774
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg + gp100 vaccine
Study: 23942774
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg + placebo
Study: 23444228
Drug: gp100 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100 vaccine alone
Study: 12707129
Drug: remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 2 micro g/kg
Study: 12707129
Drug: remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 3 micro g/kg
Study: 12707129
Drug: remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 4 micro g/kg
Study: 10972634
Drug: Naratriptan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan (2.5 mg)
Study: 11206864
Drug: Sumatriptan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (100 mg)
Study: 28540570
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg magnesium oxide supplements daily for 12 weeks
Study: 27207543
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg once daily for 10 days)
Study: 27207543
Drug: Exendin [9-39]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin [9-39] (high-dose intravenous infusion)
Study: 18468014
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg i.v. (Group M, n = 101)
Study: 18468014
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg i.v. with fentanyl 25 microg (Group MF, n = 100)
Study: 8897562
Drug: Prednisone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 40 mg/m2 on alternate days for 12 months (control group)
Study: 8897562
Drug: Prednisone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 40 mg/m2 on alternate days for 12 months plus a 90‐day course of daily cyclophosphamide, 2.5 mg/kg in a single morning dose (experimental group)
Study: 1510519
Drug: Automated closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated closed-loop titration system
Study: 1510519
Drug: Manual nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual nitroprusside titration
Study: 16336487
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of a new uro-selective alpha-blocker
Study: 16336487
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of a new uro-selective alpha-blocker
Study: 16336487
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of a new uro-selective alpha-blocker
Study: 12386911
Drug: SCOFF administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCOFF administered orally
Study: 12386911
Drug: SCOFF administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCOFF administered in written format
Study: 12386911
Drug: SCOFF administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCOFF administered verbally first
Study: 8576893
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy including a diuretic
Study: 8576893
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy without a diuretic
Study: 8576893
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug treatment (hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem-SR, prazosin)
Study: 19801363
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonists (exenatide, liraglutide)
Study: 19801363
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (sitagliptin, alogliptin, saxagliptin)
Study: 19801363
Drug: Monotherapy (diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (diet and exercise)
Study: 19801363
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (oral antihyperglycemic regimens)
Study: 12032025
Drug: Ondansetron continuous
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron continuous infusion (1 mg. mL(‐1). h(‐1))
Study: 9442775
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (5 fractions of 200 cGy 6 MV external beam photons)
Study: 7633300
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment at Clinic 2 (long-term maintenance)
Study: 7633300
Drug: Time-limited treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-limited treatment aimed at abstinence at Clinic 1
Study: 7633300
Drug: Methadone dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone dose of 80 mg/day
Study: 7633300
Drug: Average doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average doses prescribed in Clinic 1 (lower doses)
Study: 2520344
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (approximately 28 mg delivered into the mouth)
Study: 238278
Drug: Trimepranol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimepranol (15 mg daily for 16 weeks)
Study: 29681434
Drug: Ruxolitinib 15
Normalized name: ruxolitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 15 mg b.i.d. plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Study: 29681434
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Study: 28886745
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (optimal dose)
Study: 26259064
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) drugs
Study: 8704804
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 1 mg/kg injected transvaginally or 1.5 mg/kg IM if necessary (group 1)
Study: 6666698
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie referencing with no further calorie goals
Study: 30767504
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask
Study: 20622335
Drug: Compound Polygonum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Polygonum multiflorum extract
Study: 20622335
Drug: Naofukang (western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naofukang (western medicine control)
Study: 12354084
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment using curettes
Study: 10407818
Drug: Doxapram (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (0.5 mg/kg/h continuous infusion)
Study: 10407818
Drug: Theophylline (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (loading dose 5 mg/kg, 3 mg/kg bid)
Study: 2075080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both agents (Cefuroxime + Metronidazole)
Study: 28597604
Drug: Lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 400 mg
Study: 27826183
Drug: Lesinurad 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 1,600 mg (supratherapeutic dose)
Study: 22528707
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs) - metoprolol, propafenone, verapamil